A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
<p>Abstract</p> <p>Background</p> <p>The addition of bevacizumab to standard chemotherapy prolongs progression free survival in the first line treatment of epithelial ovarian cancer (EOC), but its cost/effectiveness is debated. We assessed the safety and activity of a l...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-06-01
|
| Series: | Journal of Ovarian Research |
| Online Access: | http://www.ovarianresearch.com/content/5/1/17 |